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S everal large clinical trials have demonstrated that antivascular endothelial growth factor (VEGF) 
therapy is an effective and safe treatment for macular 
edema (ME) due to branch retinal vein occlusion 
(BRVO) [1-6],  and anti-VEGF therapy is currently the 
first-line treatment for ME due to BRVO.  However,  an 
appropriate treatment protocol for this therapy has not 
been established [7].  One reason for this problem is that 
the required frequency of anti-VEGF injections varies 
greatly from patient to patient.  Although there have 
been reports that ME resolves spontaneously in 18-41% 
of BRVO cases [8 , 9],  it has also been reported that 50% 
of cases require continued anti-VEGF treatment even 
after 4 years of anti-VEGF therapy [9].
Several clinical trials have used a protocol that 
includes switching to a pro re nata regimen (PRN) after 
6 months of monthly administrations of anti-VEGF 
therapy [1 , 3 , 5].  However,  even the first six monthly 
injections can lead to overtreatment and a serious 
patient burden.  To further complicate matters,  a PRN 
regimen can be insufficient to treat some patients with 
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We investigated the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections for 
macular edema (ME) due to branch retinal vein occlusion (BRVO).  We retrospectively examined 2-year results 
of 32 eyes of 32 patients who underwent TAE to treat ME due to BRVO.  The patients whose treatment interval 
extended to ≥ 12 weeks were switched to a pro re nata regimen (PRN).  For the patients whose treatment interval 
was < 12 weeks,  TAE was continued.  At 2 years,  10 eyes had required no additional injections after the initial 
treatment period [recurrence(−) group],  whereas the other 22 eyes required additional treatment [recur-
rence(+) group].  Among the recurrence(+) patients,  11 eyes (34.4% of total) were eventually switched from 
TAE to PRN; the other 11 eyes (34.4%) continued TAE for 2 years.  Visual acuity and central retinal thickness 
were significantly improved in both the recurrence(+) and (−) groups,  and there was no significant between-
group difference in visual acuity at 2 years.  Univariate analyses revealed significant differences in visual acuity 
(p= 0.004),  age (p= 0.014),  and vessel occlusion site (p= 0.018) between these groups.  Our results suggest that 
TAE may be effective for BRVO patients with lower visual acuity,  older age,  and occlusion of a major vein.
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ME due to BRVO.  Therefore,  in order to minimize the 
number of treatments and reduce the burden on the 
patient,  an individualized administration regimen is 
desirable.
A treat-and-extend regimen (TAE) is an individual-
ized administration method which aims to reduce the 
number of consultations by determining the optimal 
treatment interval [10-12].  TAE regimens have mainly 
been used for the administration of anti-VEGF therapy 
to treat age-related macular degeneration,  but these 
regimens have also been used to treat ME due to BRVO 
[13 , 14].  We conducted a study of the 1-year results 
following a TAE regimen for ME due to BRVO,  and we 
observed that TAE regimens were effective and that 
there were large individual differences in reactivity to 
anti-VEGF treatment [15].  In the present study,  we 
report the 2-year therapeutic results of a TAE regimen 
of anti-VEGF injections for ME due to BRVO.
Patients and Methods
Patient sample and study design. We retrospec-
tively reviewed the medical records of 32 eyes of 32 
consecutive patients (14 men,  18 women; mean age ± 
SD,  71.3 ± 11.2 years) with treatment-naïve ME due to 
BRVO who were treated at Okayama University 
Graduate School of Medicine,  Dentistry and Phar-
maceutical Sciences.  The patients began treatment 
between October 2013 and November 2014 and were 
each administered intravitreal injections of ranibi-
zumab (0.5 mg; Lucentis,  Genentech/Novartis,  San 
Francisco,  CA,  USA) according to a TAE regimen.  All 
patients continued treatment with this regimen for ≥ 2 
years.  This study was approved by the Institutional 
Review Board of Okayama University Graduate School 
of Medicine,  Dentistry and Pharmaceutical Sciences 
(approval No. 1506-043) and was conducted in accor-
dance with the tenets of the Declaration of Helsinki.  
Each patient was informed of the risks and benefits of 
treatment and gave written informed consent to partic-
ipate.
Ophthalmological examination. All patients 
underwent comprehensive ophthalmologic examina-
tions at all visits,  including the measurement of his or 
her best-corrected visual acuity (BCVA) with refraction 
using the 5-m Landolt C acuity chart and indirect and 
contact lens slit lamp biomicroscopy.  The patients’ 
BCVA values were recorded as decimal values and con-
verted to logarithm of the minimum angle of resolution 
(logMAR) units for the statistical analyses.  The diagno-
ses of ME due to BRVO were based on the results of 
fundus examinations,  fluorescein angiography 
(TRC50DX; Topcon Medical Systems,  Tokyo),  and 
optical coherence tomography (OCT) (Cirrus: Carl 
Zeiss Meditec,  Jena,  Germany and DRI OCT-1 
Atlantis: Topcon Medical Systems).  We defined ME as 
a central retinal thickness (CRT) measurement >300 μm,  
as determined by OCT.  Patients with a history of 
thromboembolic events were excluded from this study.
The treat-and-extend regimen. Intravitreal injec-
tions of ranibizumab were administered to all 32 
patients as described [15].  Briefly,  the patients were 
examined and injected with ranibizumab every 4 weeks 
until no sign of ME was found.  If there was no sign of 
ME,  a new injection was given,  and the time interval 
until the next treatment was extended by 4 weeks at a 
time,  to a maximum interval of 12 weeks.  If an OCT 
examination revealed recurrence,  defined as a CRT 
> 300 μm,  the interval was shortened by 2 weeks at a 
time until the CRT became ≤ 300 μm.  Patients whose 
treatment interval was extended to 12 weeks were sub-
sequently switched from the TAE regimen to a PRN 
regimen.
Thus,  if a patient’s ME did not recur at all after the 
initial injection,  the treatment regimen was shifted to a 
PRN regimen after four doses,  i.e.,  6 months after the 
initial injection (Fig. 1).  Patients who showed a retinal 
non-perfusion area > 10 optic discs area (DA) at 6 
months after the initial injection were treated with reti-
nal photocoagulation.
Outcome measures. The main outcome measures 
were as follows: (1) the individualized therapeutic pro-
tocols; (2) changes in the BCVA,  CRT,  and the annual 
number of intravitreal ranibizumab injections; and (3) 
predictive factors for the recurrence of ME.
Statistical analyses. Both the BCVA and CRT 
were compared at baseline,  1 month,  6 months,  1 year,  
and 2 years after the initial injection by a one-way anal-
ysis of variance (ANOVA) with a Bonferroni correction.  
To explore the predictive factors for the absence of ME 
recurrence following intravitreal ranibizumab treatment 
by a modified TAE regimen,  we analyzed clinical char-
acteristics including age,  disease duration,  BCVA,  and 
CRT by unpaired t-tests.  The site of occlusion,  the pres-
ence/absence of a 10-DA nonperfusion area,  the pres-
ence/absence of serous retinal detachment,  and the 
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presence/absence of hypertension at baseline were ana-
lyzed using Pearson’s chi-square tests.  Probability val-
ues < 0.05 were considered significant.  All statistical 
analyses were performed using SPSS for Windows ver. 
17.0 (SPSS,  Chicago,  IL,  USA).  Unless otherwise noted,  
the data are presented as means ± standard deviation.
Results
Thirty-two eyes of 32 Japanese patients were ana-
lyzed.  The patients’ baseline characteristics are summa-
rized in Table 1.  Figure 1 provides a summary of the 
individualized treatment protocols for all patients 
during the 2-year study period.  At 2 years,  10 eyes 
(31.3%) had not shown any recurrence of ME after the 
initial injection; these patients comprised the recur-
rence(−) group.  The other 22 eyes (68.7%) did show a 
recurrence of ME and required additional treatment;  
these patients were the recurrence(+) group.
In the recurrence(+) group,  11 of the total 32 eyes 
(34.4%) were able to eventually change from the TAE 
regimen to a PRN regimen,  and the other 11 recur-
rence(+) eyes of the total 32 eyes (34.4%) continued the 
TAE regimen for 2 years.  Ten of the 15 eyes in which 
ME did not recur for 6 months after the initial injection 
did not show any recurrence throughout the follow-up 
period,  and the remaining 5 eyes showed a recurrence 
of ME; the interval of the recurrence was 16-28 weeks 
after the initial injection.
Seventeen eyes showed a recurrence of ME during 
the first 6 months after the initial injection,  and 11 
(65%) of these 17 cases required repeated injections at 
intervals of < 12 weeks throughout the second year.  The 
treatment intervals at 2 years for all cases are shown in 
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???? ?　 Summary of the therapeutic protocol for all patients during the 2-year study period.  TAE,  treat-and-extend; ME,  macular 
edema; PRN,  pro re nata.
????? ?　 Baseline patient characteristics
Cases 32
Age (years) 71.3±11.2
Sex (male/female) 14/18
Time period from onset of BRVO to initial injection 
(months) 1.9±1.6
Major BRVO/Macular BRVO 20/12
NPA ≥10DA (eyes (%)) 11 (34.4)
SRD (eyes (%)) 14 (43.8)
Hypertension (eyes (%)) 20 (62.5)
Data are presented as the mean ± standard deviation
BRVO,  branch retinal vein occlusion; NPA,  non-perfusion area;  
DA,  discs area; SRD,  serous retinal detachment.
Fig. 2.
The patients’ BCVA (logMAR) improved signifi-
cantly,  from a mean of 0.40 ± 0.34 at baseline to 
0.10 ± 0.22 and 0.07 ± 0.19 at 1 year and 2 years,  respec-
tively (both p < 0.001,  Fig. 3).  Further,  the mean BCVA 
(logMAR) improved significantly in both the recur-
rence(−) group and the recurrence(+) group.  In the 
recurrence(−) group,  the mean BCVA (logMAR) 
improved from 0.22 ± 0.10 at baseline to −0.01 ± 0.12 
and −0.02 ± 0.11 at 1 year and 2 years,  respectively 
(both p < 0.001,  Fig. 3).  The mean BCVA (logMAR) for 
the recurrence(+) group improved from 0.49 ± 0.37 at 
baseline to 0.15 ± 0.24 and 0.11 ± 0.20 at 1 year and 2 
years,  respectively (both p< 0.001,  Fig. 3).  There was no 
significant difference between the BCVAs of the 2 
groups at 2 years (Table 2,  Fig. 3).
The CRT decreased significantly,  from a mean of 
448.6 ± 115.1 μm at baseline to 272.3 ± 70.5 μm and 
252.9 ± 36.3 μm at 1 year and 2 years,  respectively (both 
p < 0.001,  Fig. 4).  This significant decrease was seen in 
both the recurrence(−) group and the recurrence(+) 
group.  In the recurrence(−) group,  the mean CRT 
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???? ?　 Course of visual acuity.  The mean BCVA measured at 
baseline,  1 month,  6 months,  1 year,  and 2 years in the total 
patient group,  the recurrence(+) group,  and the recurrence(－) 
group.  In each group,  visual acuity was signiﬁcantly improved at 
each time point compared to baseline.  logMAR,  logarithm of the 
minimum angle of resolution.  ＊p＜0.01.
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???? ?　 Treatment interval at 2 years.  Individual patients demon-
strated a wide variation in the maximum treatment interval.  At 2 
years after the initial treatment,  21 eyes (65.6%) had achieved a 
treatment interval of ≥12 weeks,  and the other 11 eyes (34.4%) 
required a treatment interval of ＜12 weeks.
????? ?　 Comparison of baseline characteristics between the no recurrence group and the recurrence group
No recurrence
(n＝10)
Recurrence
(n＝22) p value
Age (years) 62.0±14.0 75.6±6.5 0.014
Sex (male/female) 5/5 9/13 0.699
Time period from onset of BRVO to initial injection (months) 2.1±1.9 1.9±1.5 0.794
BCVA at baseline (logMAR) 0.22±0.10 0.49±0.37 0.004
CRT at baseline (μm) 460.9±128.4 443.0±111.4 0.692
Major BRVO/Macular BRVO 3/7 17/5 0.018
NPA ≥10DA (eyes (%)) 1 (10.0) 10 (52.6) 0.106
SRD (eyes (%)) 6 (60.0) 8 (42.1) 0.267
Hypertension (eyes (%)) 7 (70.0) 11 (57.9) 0.703
Data are presented as the mean ± standard deviation
TAE,  treat-and-extend regimen; PRN,  pro re nata; BRVO,  branch retinal vein occlusion; BCVA,  best-corrected visual acuity; CRT,  cen-
tral retinal thickness; NPA,  non-perfusion area; SRD,  serous retinal detachment.
decreased significantly,  from 460.9 ± 128.4 μm at base-
line to 253.4 ± 52.9 μm and 229.7 ± 18.4 μm at 1 year and 
2 years,  respectively (both p < 0.001,  Fig. 4).  For the 
recurrence(+) group,  the mean CRT decreased signifi-
cantly from 443.0 ± 111.4 μm at baseline to 280.9 ± 76.7  
μm and 258.2 ± 37.4 μm at 1 year and 2 years,  respec-
tively (both p < 0.001,  Fig. 4).  No significant difference 
was observed in the CRT between the recurrence(−) 
and recurrence(+) groups at baseline,  1 month,  6 
months,  or 1 year (Table 2,  Fig. 4).  However,  at 2 years 
the mean CRT was significantly thicker in the recur-
rence(+) group compared to the recurrence(−) group 
(p = 0.03,  Fig. 4).
In the total patient group,  the mean number of 
injections was 6.0 ± 2.2 for the first year and 3.2 ± 2.9 for 
the second year.  In the recurrence(−) group,  the mean 
number of injections was 4.0 ± 0.0 for the first year and 
0.0 ± 0.0 for the second year.  For the recurrence(+) 
group,  the mean number of injections was 6.9 ± 2.1 for 
the first year and 4.6 ± 2.4 for the second year.
Our comparison of the recurrence(−) and (+) 
groups by univariate analyses revealed significant differ-
ences in visual acuity (p = 0.004),  age (p = 0.014),  and 
occlusion of a major vein (p = 0.018,  Table 2).
Discussion
A TAE regimen allows the interval of anti-VEGF 
drug injections to reflect the rate of ME recurrence in an 
individualized manner.  Herein we investigated the 
2-year results of intravitreal ranibizumab injections 
using a TAE regimen for ME due to BRVO,  and we 
noted that the recurrence frequency of ME after treat-
ment varied among patients.  There was no recurrence 
of ME after the initial treatment in 31.3% of all of the 32 
patients,  whereas 34.4% of the patients showed ME 
recurrence and required injection intervals of < 12 
weeks at 2 years after the initial treatment.
The RETAIN study used a treatment protocol that 
included switching from monthly ranibizumab injec-
tions to PRN injections,  and the RETAIN authors 
reported that 48% of their patients had a recurrence of 
their ME within 6 months of the initial treatment [4].  
Guichard et al.  administered ranibizumab injections 
using a TAE regimen for ME due to retinal vein occlu-
sion,  and they reported that at 2 years after the initial 
treatment,  the treatment interval was ≥ 12 weeks in 
42% of all cases and < 10 weeks in 58% of the cases [14].  
The diversity of ME recurrence reported in these studies 
is consistent with our present findings.  It is apparent 
that because a monthly administration can be over-
treatment for patients who are less likely to have an ME 
relapse whereas PRN administration can be undertreat-
ment for patients with frequent recurrences of ME 
[16 , 17],  a TAE regimen has the potential to be an 
effective,  individualized alternative for the treatment of 
ME due to BRVO.
As shown in Table 2,  our results indicate that 
patients are less likely to experience a recurrence of ME 
if they have better visual acuity,  are younger,  or have 
macular BRVO.  These results are consistent with those 
of a previous report by our group in which we investi-
gated the 1-year results of a TAE regimen for ME due to 
BRVO [15].  Of note,  ME due to macular BRVO has 
been reported to be more likely to show spontaneous 
remission compared to ME due to major BRVO [18].  In 
addition,  macular BRVO has been reported to require 
fewer injections than major BRVO,  suggesting that 
macular BRVO is more reactive to anti-VEGF treatment 
[19 , 20].  Together these results indicate that major 
BRVO involves more widespread retinal ischemia than 
macular BRVO,  resulting in a greater production of 
VEGF and inflammatory cytokines (such as monocyte 
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???? ?　 Course of central retinal thickness (CRT).  The mean CRT 
at baseline,  1 month,  6 months,  1 year,  and 2 years in the total 
patient group,  the recurrence(+) group,  and the recurrence(－) 
group.  In each group,  the CRT was signiﬁcantly improved at each 
time point compared to baseline.  ＊p＜0.05.  ＊＊p＜0.01.
chemoattractant protein-1 [MCP-1] and interleukin 
[IL]-6) from the ischemic retina [19 , 20].
The present study has important limitations,  includ-
ing its retrospective design and small sample size.  To 
establish the optimal ranibizumab treatment protocol 
for ME due to BRVO,  randomized and prospective 
clinical studies with more patients are necessary.  
Importantly,  our TAE regimen may result in overtreat-
ment for patients who do not require any treatment 
because of spontaneous ME remission.  The enlarge-
ment of the foveal avascular zone area and the presence 
of collateral circulation in BRVO cases are factors 
related to the progression of visual acuity and macular 
morphology [21 , 22].  Further studies must investigate 
the relationship between these factors and treatment 
results of ME cases due to BRVO.  In conclusion,  our 
2-year results suggest that a TAE regimen may be espe-
cially effective for patients with lower visual acuity,  
older age,  and a major BRVO.
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